MOG and myeloid sarcoma: We showed that hPDLSCs-CM and hPDLSCs-EMVs obtained from both RR-MS patients and healthy donors were effective to significantly reduce the MOG-induced activation of CD4+ Th1 and Th17 cells in spinal cord and in spleen, an important peripheral lymphoid tissue target, in EAE mice.